Former pharmaceutical exec Martin Shkreli released from prison
Reuters
Published May 18, 2022 01:57PM ET
Updated May 18, 2022 05:02PM ET
By Jonathan Stempel
NEW YORK (Reuters) - Martin Shkreli, the former pharmaceutical executive known for raising the price of a lifesaving drug more than 40-fold, has been released from prison, where he had been serving a seven-year term for fraud.
The early release of the 39-year-old Shkreli from a low security prison in Allenwood, Pennsylvania was confirmed on Wednesday by the prison and by Benjamin Brafman, who represented Shkreli at his 2017 criminal trial.
"Martin Shkreli has been released from Allenwood prison and transferred to a BOP halfway house after completing all programs that allowed for his prison sentence to be shortened," Brafman said in a statement, referring to the Federal Bureau of Prisons.
Shkreli is eligible to be released completely from federal custody on Sept. 14. His confinement is now overseen by a New York office that helps prisoners reenter society.
Speculation about Shkreli's whereabouts grew on Wednesday after photos appeared on Twitter (NYSE:TWTR) of an older-looking man who resembled him, accompanied by a man wearing a "Free Shkreli" t-shirt.
Shkreli became known as "pharma bro" after raising the price of the anti-parisitic drug Daraprim to $750 per tablet from $17.50 in 2015, and appearing unapologetic when criticized.
He was convicted in August 2017 of defrauding investors in two hedge funds he ran, and scheming to defraud investors in drugmaker Retrophin (NASDAQ:TVTX) Inc, where he had been chief executive.
Last July, the government sold a one-of-a-kind Wu-Tang Clan album "Once Upon a Time in Shaolin" that Shkreli bought at auction for $2 million, to help pay off $7.36 million he was ordered to forfeit because of his conviction.
In January, a Manhattan judge banned Shkreli from the drug industry for life and ordered him to pay $64.6 million for trying to keep generic Daraprim rivals off the market.
The following month, the Brooklyn judge who oversaw Shkreli's criminal trial permanently banned him from serving as an officer or director of public companies.
Brafman said he has "encouraged Mr. Shkreli to make no further statement."
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.